Stockscreener 앱 받기
5.52
25.45%
1.12
시간 외 거래:
5.50
-0.02
-0.36%
전일 마감가:
$4.40
열려 있는:
$4.34
하루 거래량:
971.94K
Relative Volume:
2.85
시가총액:
$347.77M
수익:
$12.14M
순이익/손실:
$-99.50M
주가수익비율:
-4.0777
EPS:
-1.3537
순현금흐름:
$-56.37M
1주 성능:
+30.81%
1개월 성능:
+67.27%
6개월 성능:
+305.88%
1년 성능:
+633.75%
1일 변동 폭
$4.2629
$5.54
1주일 범위
$3.83
$5.54
52주 변동 폭
$0.72
$5.54
Prelude Therapeutics Inc Stock (PRLD) Company Profile
명칭
Prelude Therapeutics Inc
전화
(302) 467-1280
주소
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
5.52 | 277.21M | 12.14M | -99.50M | -56.37M | -1.3537 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2024-03-13 | 개시 | JMP Securities | Mkt Outperform |
| 2024-02-20 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | 개시 | Jefferies | Buy |
| 2022-03-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-02-28 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-10-08 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-04-26 | 개시 | H.C. Wainwright | Buy |
| 2021-03-09 | 개시 | Barclays | Overweight |
| 2020-11-20 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-10-20 | 개시 | BofA Securities | Buy |
| 2020-10-20 | 개시 | Goldman | Neutral |
| 2020-10-20 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Prelude Therapeutics Inc 주식(PRLD)의 최신 뉴스
Prelude Therapeutics Appoints Dr. Charles Morris as Chief Medical Officer to Advance Precision Oncology Pipeline - Minichart
Prelude Therapeutics (PRLD) Appoints New Chief Medical Officer - GuruFocus
Prelude Therapeutics Appoints Veteran Oncologist as New CMO - TipRanks
New CMO joins Prelude Therapeutics (NASDAQ: PRLD) as pipeline advances - Stock Titan
Prelude Therapeutics names Charles Morris as chief medical officer By Investing.com - Investing.com UK
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer - GlobeNewswire
Bull Bear: Is Prelude Therapeutics Incorporated stock a good pick for beginners2026 Stock Rankings & Capital Efficiency Focused Ideas - baoquankhu1.vn
Activity Recap: Whats the beta of Prelude Therapeutics Incorporated stockQuarterly Trade Report & Safe Capital Investment Plans - baoquankhu1.vn
Aug Swings: What is the Moat Score of Prelude Therapeutics Incorporated2026 Earnings Impact & Weekly Stock Breakout Alerts - baoquankhu1.vn
Retail Surge: Is Prelude Therapeutics Incorporated a turnaround story2026 Drop Watch & Consistent Income Trade Recommendations - baoquankhu1.vn
PRLD Technical Analysis | Trend, Signals & Chart Patterns | PRELUDE THERAPEUTICS INC (NASDAQ:PRLD) - ChartMill
Loss Report: How do insiders feel about Prelude Therapeutics IncorporatedExit Point & Scalable Portfolio Growth Methods - baoquankhu1.vn
IPO Launch: Will Prelude Therapeutics Incorporated stock go up in YEARMarket Performance Recap & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Prelude Therapeutics Incorporated (PRLD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Prelude Therapeutics reports 2025 results and advances oncology pipeline - MSN
PRLD Technical Analysis & Stock Price Forecast - Intellectia AI
Rate Hike: Is Prelude Therapeutics Incorporated backed by strong institutional buying2026 Drop Watch & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Marker Therapeutics (NASDAQ:MRKR) & Prelude Therapeutics (NASDAQ:PRLD) Financial Survey - Defense World
If You Invested $1,000 in Prelude Therapeutics Inc (PRLD) - Stock Titan
PRLD PE Ratio & Valuation, Is PRLD Overvalued - Intellectia AI
Value Recap: How do insiders feel about Prelude Therapeutics IncorporatedChart Signals & Community Consensus Trade Alerts - baoquankhu1.vn
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting - The Manila Times
Prelude Therapeutics Reports 2025 Results and Advances Oncology Pipeline - MyChesCo
Prelude Therapeutics Inc. Files Form 8-K with SEC – Company Information and Legal Exhibit Details (March 12, 2026) - Minichart
Prelude Therapeutics Establishes New ATM Equity Offering Facility - The Globe and Mail
Prelude Therapeutics files to offer up to $25 million in stock through Jefferies By Investing.com - Investing.com South Africa
Prelude Therapeutics files to offer up to $25 million in stock through Jefferies - Investing.com
Prelude Therapeutics 2025 Annual Report: Precision Oncology Pipeline, Business Strategy, and Regulatory Overview - Minichart
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate, Shares Surge 11.8% - AlphaStreet
ADC Therapeutics SA (ADCT) Reports Wider Loss Q4 EPS Estimates by 85.1% - AlphaStreet
Prelude Therapeutics (NASDAQ:PRLD) Price Target Raised to $6.00 at Citizens Jmp - MarketBeat
Citizens Analyst Raises Price Target for Prelude Therapeutics (P - GuruFocus
Citizens raises Prelude Therapeutics price target on JAK2 potential By Investing.com - Investing.com Canada
Prelude Therapeutics (PRLD) Q4 Loss Per Share Narrows Challenging Longstanding Bearish Narratives - simplywall.st
PRLD: Pipeline refocused on JAK2 V617F and KAT6A, with strong funding and key Incyte partnership - TradingView
Cullinan Therapeutics Inc (CGEM) Reports Q4 Earnings - AlphaStreet
Prelude Therapeutics (PRLD) Q4 Loss Widens 616.7% to $1.29/Share as Revenue Climbs to $12.1M - AlphaStreet
Prelude Therapeutics Inc (PRLD) Reports Wider Loss for FY25 vs. Estimates - AlphaStreet
Prelude Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Prelude Therapeutics 2025 10-K: Revenue $12.14M, EPS (1.29) - TradingView
Prelude Therapeutics (NASDAQ:PRLD) Posts Quarterly Earnings Results, Beats Estimates By $0.13 EPS - MarketBeat
PRLD: Secured $60M upfront from Incyte, boosting cash and extending runway into Q2 2027 - TradingView
Prelude Therapeutics (PRLD) Advances Key Drug Programs with IND Clearance - GuruFocus
Prelude Therapeutics Earnings Report: Q4 Overview - Benzinga
Prelude Therapeutics reports $99.5 mln net loss for 2025 - TradingView
BRIEF-Prelude Therapeutics FY EPS USD -1.29 - TradingView
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 - ChartMill
Aug Analyst Calls: Can Prelude Therapeutics Incorporated outperform under higher oil prices2025 Risk Factors & Fast Gain Swing Alerts - baoquankhu1.vn
Prelude Therapeutics Inc expected to post a loss of 3 cents a shareEarnings Preview - TradingView
Volume Report: Is Prelude Therapeutics Incorporated a cyclical or defensive stockQuarterly Earnings Report & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Prelude Therapeutics (PRLD) Expected to Announce Earnings on Monday - MarketBeat
Prelude Therapeutics Inc (PRLD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):